Precigen, Inc. (PGEN) News
Follow Precigen, Inc. (PGEN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Precigen Shares Fall 20% in Premarket Trading
Precigen shares plunged 20% in premarket trading Monday. The decline comes ahead of Wednesday’s earnings and as Inovio’s newly approved rival challenges Precigen’s Papzimeos treatment.
EQUITY | Nov 02, 2026, 08:40 AM UTC
M
Precigen to Report Third-Quarter Financial Results
Precigen says it will release its third-quarter 2026 financial results.
EQUITY | Oct 28, 2026, 08:18 PM UTC
L
Weekly Recap: Papzimeos FDA approval and Analyst Buy with $12 target
Precigen Inc (NASDAQ:PGEN) is shifting from clinical-stage to commercial launch after FDA approval of Papzimeos for recurrent respiratory papillomatosis, while an analyst initiated Buy coverage with a $12 target, citing
REGULATION | Sep 28, 2026, 11:06 AM UTC
L
MRNA, PGEN Stocks Hit Multi-Year Highs — What’s Driving The Momentum Today?
Moderna (MRNA) and Precigen (PGEN) hit new milestones on Friday, as investors weighed fresh Wall Street commentary on the biotech companies’ cancer-focused therapies.MRNA shares gained 1.5% to their highest level since J
EQUITY | Sep 25, 2026, 06:37 PM UTC
L
B. Riley Securities initiates coverage of Precigen with Buy rating, $12 price target
B. Riley Securities initiated coverage on Precigen's stock with a rating of Buy and a price target of $12.00.The price target implies an upside of 55.8% from the Sep 24 close of $7.70.Key takeaways from the analyst noteS
EQUITY | Sep 25, 2026, 03:57 PM UTC
L
Precigen Initiated at Buy by B. Riley Securities
Ratings actions from Benzinga: GMT) Precigen Price Target Announced at $12.00/Share by B. Riley SecuritiesRatings actions from Benzinga
NEWS | Sep 25, 2026, 09:31 AM UTC
M
Precigen gets FDA platform technology designation for Adenoverse
Precigen, Inc. (NASDAQ:PGEN) said it received an FDA platform technology designation for its Adenoverse platform.
REGULATION | Sep 21, 2026, 12:10 PM UTC
L
PGEN - Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
PGEN - Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
REGULATION | Sep 21, 2026, 11:00 AM UTC
L
Precigen director sold shares worth over $1.3M
A Precigen director sold shares worth over $1.3M.
EQUITY | Aug 29, 2026, 12:40 AM UTC
M
Precigen PGEN touts strong Q2 growth; PRGN-2009 HPV-cancer progress
Precigen (PGEN) reports a strong second quarter, saying it signals significant growth and validates its AdenoVerse platform, while highlighting PRGN-2009 advances in HPV-driven cancers.
EQUITY | Aug 25, 2026, 11:00 AM UTC
L
PGEN September 8 calls offered, 6K at $0.25 expiring Sep. 18
PGEN September 8 call activity is on offer for 6,000 contracts at $0.25, with expiry on Sep. 18; no catalyst was supplied.
EQUITY | Aug 20, 2026, 02:16 PM UTC
H
HC Wainwright Raises PGEN Price Target
Raises PGEN target to $18 from $14
EQUITY | Aug 05, 2026, 11:11 AM UTC
H
Why Arista Networks Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Shares of Arista Networks Inc (NYSE: ANET ) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued strong third-quarter guidance. Arista Networks re
EARNINGS | Aug 05, 2026, 08:57 AM UTC
L
PGEN PGEN - Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth
PGEN PGEN - Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth
EARNINGS | Aug 04, 2026, 08:02 PM UTC